To Hideto
Clinical Pharmacokinetics, Division of Clinical Pharmacy, Department of Medico-Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Yakugaku Zasshi. 2006 Jun;126(6):415-22. doi: 10.1248/yakushi.126.415.
Metastatic breast cancer (MBC) is almost always incurable, and the median survival is of the order on 18-24 months. Combination therapy with adriamycin (ADR) and docetaxel (DOC) is more effective against MBC than the previous therapy due to differences between their mechanisms. However, the combination of ADR and DOC induces severe adverse effects, limiting its clinical use in many patients with MBC. The biologic functions of most living organisms are organized along an approximate 24 h time cycle or circadian rhythm. Chronotherapy is defined as the administration of medications using biological rhythms to optimize the therapeutic outcomes and/or control adverse effects. To decrease adverse effects, many antitumor drugs have been particularly studied in humans and animals. The toxicities of ADR and DOC have also been found to depend on dosing-time in animals and humans. This study was to establish the most suitable dosing schedule to relieve severe adverse effects and improve antitumor effects by considering a chronopharmacological approach, dosing-interval and dosing-sequence to the combination chemotherapy of ADR and DOC in mice. In the results, we demonstrate that the dosing schedule based on dosing-sequence, dosing-interval and dosing-time not only significantly reduced leukopenia and toxic death but also significantly increased the inhibition rate of tumor growth compared with the dosing schedule without an interval between each injection, commonly used in clinical practice. These findings suggest that the therapeutic index of combined chemotherapy can be improved by choosing an optimal dosing-schedule (dosing-interval, dosing-sequence and dosing-time).
转移性乳腺癌(MBC)几乎总是无法治愈的,中位生存期约为18至24个月。由于阿霉素(ADR)和多西他赛(DOC)作用机制不同,二者联合治疗MBC比之前的治疗方法更有效。然而,ADR与DOC联合使用会引发严重的不良反应,限制了其在许多MBC患者中的临床应用。大多数生物体的生物学功能是按照大约24小时的时间周期或昼夜节律来组织的。时间治疗法的定义是利用生物节律给药,以优化治疗效果和/或控制不良反应。为了减少不良反应,人们对许多抗肿瘤药物进行了专门的人体和动物研究。研究还发现,ADR和DOC的毒性在动物和人类中也取决于给药时间。本研究旨在通过考虑时间药理学方法、给药间隔和给药顺序,为ADR与DOC联合化疗建立最合适的给药方案,以减轻严重的不良反应并提高抗肿瘤效果。结果表明,与临床实践中常用的每次注射之间无间隔的给药方案相比,基于给药顺序、给药间隔和给药时间的给药方案不仅显著降低了白细胞减少症和毒性死亡的发生率,还显著提高了肿瘤生长抑制率。这些发现表明,通过选择最佳给药方案(给药间隔、给药顺序和给药时间)可以提高联合化疗的治疗指数。